Additional early-stage research and drug discovery news in brief, from: Corvus Pharmaceuticals, Panavance Therapeutics.

Etnova Therapeutics Co. Ltd. has described gadolinium complexes reported to be useful for the treatment of stroke, ataxia, epilepsy, spinal cord injury, optic nerve injury, Alzheimer’s disease, Parkinson’s disease and Huntington’s disease, among others.

Yonsei University has divulged protein kinase inhibitors and/or degradation inducers reported to be useful for the treatment of cancer.

Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has identified EGFR (HER1; erbB1) wild-type and/or mutant inhibitors reported to be useful for the treatment of cancer, particularly non-small-cell lung cancer (NSCLC).

Deciphera Pharmaceuticals LLC has synthesized heterocyclic compounds acting as eukaryotic translation initiation factor 2-α kinase 3 (PERK) and/or GCN2 inhibitors reported to be useful for the treatment of cancer and amyloidosis.

Suzhou Genhouse Bio Co. Ltd. has disclosed son of sevenless homolog 1 (SOS1) inhibitors reported to be useful for the treatment of cancer and more.

Recent genome-wide association studies have elucidated a spliced variant (rs72613567:TA) in 17β-hydroxysteroid dehydrogenase 13 (HSD17B13) found to be associated with decreased risk of chronic liver disorders. The presence of this variant also correlates with delayed onset of autoimmune hepatitis in carriers.